Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


UK universities need more than ABB grades to compete in the global market

22 August 2013

By Prof Stephen Caddick, University College London
Each year, right in the middle of August's silly season, we see the same old proclamations from the media, politicians and university dons about A-Level grades.

This year the debate has been enriched further with a good healthy dollop of nonsense about competition. Now that universities can take an unrestricted number of students with ABB or above the hype would have it that we are all ruthlessly battling for students and their valuable fees. 

Read the full article